Effects of chronic GLP-1/GIP and GLP-1/GIP/glucagon agonist treatments on high-fat diet fed 3xTg-AD mice (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR262.30 / W9; Pres time: Nov 17, 2026; 01:00 PM - 05:00 PM; Location: WCC Halls A-C; "To assess this, we investigated the effects of the dual GLP-1/GIP agonist tirzepatide (TIRZEP) and the triple GLP-1/GIP/glucagon agonist retatrutide (RETA) in male and female 3xTg-AD mice...These data suggest that multi-agonist incretin therapies may improve metabolic dysfunction and select behavioral outcomes in AD under conditions of diet-induced metabolic stress. If supported by ongoing neuropathological analyses (amyloid-β, tau, neuroinflammation), this work could help establish incretin-based drugs as promising candidates for treating AD patients with obesity, diabetes, or related metabolic comorbidities."
Preclinical • Alzheimer's Disease • CNS Disorders • Mood Disorders
|
|
R. C. SPETH1; A. STANISAVLJEVIC2; N. NOTO3; K. MARTIN4; D. KUNI5; V. PULIDO-CORREA6; A. ARIAS7; G. SURESH8; I. PATEL5; M. PATEL8; L. MARCANO RAMOS10; M. S. PARMAR9; L. S. ROBISON8
|